Hepatitis C Pill Rockets Gilead Into Big Leagues

Gilead Sciences's new hepatitis C treatment, Sovaldi, had $3.48 billion in second-quarter sales, more than expected, continuing its historic drug launch.



from WSJ.com: US Business http://ift.tt/1x3kfdP

via IFTTT